Structure activity of 3-Aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors

Journal of Medicinal Chemistry

Volumn 45, Issue 15, 2002, Pages 3184-3194

  Pais, Godwin C G ^a   Zhang, Xuechun ^a   Marchand, Christophe ^a   Neamati, Nouri ^a   Cowansage, Kiriana ^a   Svarovskaia, Evguenia S ^a   Pathak, Vinay K ^a   Tang, Yun ^a   Nicklaus, Marc ^a   Pommier, Yves ^a   Burke Jr , Terrence R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLOROINDOL 3 YL) 3 HYDROXY 3 (1H TETRAZOL 5 YL)PROPENONE; 2 HYDROXY 4 OXO 2 BUTENOIC ACID DERIVATIVE; 4 [(3,5 DIBENZYLOXY)PHEN 1 YL] 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; DIKETONE; DIKETONE DERIVATIVE; INTEGRASE INHIBITOR; L 708 906; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

ACETOACETATES; ANTI-HIV AGENTS; CELL LINE; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; INDOLES; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES; TRANSFECTION; VIRUS REPLICATION;

EID: 0037130159     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020037p     Document Type: Article

References (48)

1. Structure-activity investigation of 3-aryl-1,3-diketo containing compounds as HIV-1 integrase inhibitors
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. HIV chemotherapy
4. Requirement of active human immunodeficiency virus type 1 integrase for productive infection of human T-lymphoid cells
5. Inhibitors of human immunodeficiency virus integrase
6. Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules
7. Retroviral integrase inhibitors year 2000: Update and perspectives
8. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design
9. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase
10. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters
11. Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: Putative inhibitors of HIV-1 integrase
12. Inhibition of HIV-1 integrase activity and HIV-1 replication by a series of diketo derivatives
13. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
14. Structural determinants for HIV-1 integrase inhibition by β-diketo acids
15. Structure-based HIV-1 integrase inhibitor design: A future perspective
16. Human immunodeficiency virus type 1 integrase-targeted inhibitor design
17. Inhibition of HIV-1 integrase by small molecules: The potential for a new class of AIDS chemotherapeutics
18. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells
19. The chemistry of bacteria. Part VI. The synthesis of a trimethyl derivative of the C20 acid from violacein
20. 5-Tetrazolecarboxamides and their salts: New orally active antiallergy agents
21. Refined model of the HIV-1 integraseviral DNA complex used for inhibitor docking studies
22. Structural and functional insights provided by crystal structures of DNA polymerases and their substrate complexes
23. Isosterism and molecular modification in drug design
24. Bioisosterism: A rational approach in drug design
25. In vitro human immunodeficiency virus type 1 integrase assays
26. Molecular modeling of full-length HIV-1 integrase and its complexes with viral and human DNA
27. A fast flexible docking method using an incremental construction algorithm
28. Charmm - A program for macromolecular energy, minimization, and dynamics calculations
29. All-atom empirical potential for molecular modeling and dynamics studies of proteins
30. All-atom empirical force field for nucleic acids: I. Parameter optimization based on small molecule and condensed phase macromolecular target data
31. Styrylpyrazoles, styrylisoxazoles, and styrylisothiazoles - Novel 5 lipoxygenase and cyclooxygenase inhibitors
32. Five-member 2,3-dioxoheterocycles. 5. Synthesis of 1-aryl-4-aroyl-5-methoxycarbony1-2,3-dihydro-2,3-pyrrolediones - Their interaction with water and alcohols
33. Homolytic acylation of protonated pyridines and pyrazines with alpha-keto acids - The problem of monoacylation
34. Homolytic acylation of protonated pyridine and pyrazine derivatives
35. Synthesis and biological activity of some azoles and azines
36. A convenient synthesis of 3-acylindoles via friedel-crafts acylation of 1-(phenylsulfonyl)indole - A new route to pyridocarbazole-5,11-quinones and ellipticine
37. Total synthesis and comparative evaluation of luzopeptin A-C and quinoxapeptin A-C
38. Substituted 3-(phenylmethyl)-1H-indole-5-carboxamides and 1-(phenylmethyl)indole-6-carboxamides as potent, selective, orally active antagonists of the peptidoleukotrienes